Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
Clin Dermatol ; 40(4): 397-401, 2022.
Article in English | MEDLINE | ID: covidwho-1788026

ABSTRACT

A wide range of extrapulmonary manifestations in patients with COVID-19 has been reported during the ongoing pandemic, thus making the clinical spectrum of this new disease very heterogeneous. While COVID-19-associated vasculitis and vasculopathy have been described, cutaneous leukocytoclastic vasculitis (cLcV) due to SARS-CoV-2 has rarely been reported, and if it has, with relatively mild courses. We present the case of a 93-year-old man who, after having survived classic COVID-19 infection, developed a fulminant cLcV leading to extensive skin necrosis and tissue damage that resulted in his death. Considering the negative workup for other triggers of vasculitis, we find that cLcV is a secondary manifestation of COVID-19, even though SARS-CoV-2 polymerase chain reaction in the skin biopsy was not present in the tissue. We hypothesize this by providing a pathophysiologic rationale (eg, SARS-CoV-2-induced endotheliitis, complement activation, and interleukin 6 dominant intra- and perivascular inflammation).


Subject(s)
COVID-19 , Skin Diseases, Vascular , Vasculitis, Leukocytoclastic, Cutaneous , Vasculitis , Aged, 80 and over , COVID-19/complications , Humans , Interleukin-6/adverse effects , Male , Necrosis/pathology , SARS-CoV-2 , Skin/pathology , Skin Diseases, Vascular/pathology , Vasculitis/complications , Vasculitis, Leukocytoclastic, Cutaneous/etiology
SELECTION OF CITATIONS
SEARCH DETAIL